FDA 483 OBSERVATION · #983 OF 1,000 MOST-CITED
Sampling/testing of labeling/packaging materials
FDA cited this observation 14 times across 14 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
How FDA worded it — real examples
Labeling and packaging materials are not representatively sampled, examined and tested upon receipt and before use in packaging and labeling of a drug product.
Labeling and packaging materials are not representatively sampled, examined and tested upon receipt and before use in packaging and labeling of a drug product.
Labeling and packaging materials are not representatively sampled and examined upon receipt and before use in packaging and labeling of a drug product.
Labeling and packaging materials are not representatively sampled and examined upon receipt and before use in packaging and labeling of a drug product.
Labeling and packaging materials are not representatively sampled, examined and tested upon receipt and before use in packaging and labeling of a drug product.
Labeling and packaging materials are not representatively sampled upon receipt and before use in packaging and labeling of a drug product.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.